Physiomics completes UK grant project for cancer treatment

Writer, Stock Market Wire
Monday, March 12, 2018 - 09:31

Physiomics said it had successfully completed a UK grant project related to improving cancer treatments that received £131k of state funding.

The project, dubbed 'Decision Support System For Stratified Cancer Treatment' analysed data from over 400 oesophageal cancer patients to determine factors that could help guide treatment. It also created a tool for healthcare professionals to visualise the data.

'The results and learnings from the project have potential applications in both the company's existing business advising R&D based pharmaceutical and biotech companies as well as in the emerging field of personalised cancer treatment,' the company said.

'In order to further develop the technology the company is actively seeking additional grants in this space.'

At 9:31am: (LON:PYC) Physiomics PLC share price was +0.1p at 5.03p

Related content

Physiomics extends collaboration agreement with Merck

Physiomics said it had extended a collaboration pact with Merck for the next calendar year related to cancer treatments.

Physiomics and Merck had entered into...

Mon, 17/12/2018 - 08:14

Physiomics losses narrow after contract wins

Cancer treatment evaluation group Physiomics said its annual losses narrowed after it almost doubled its revenue.

Pre-tax losses for the year through June amounted to...

Mon, 08/10/2018 - 08:24

Physiomics says it is anticipated to beat market expectations

Physiomics confirmed that based on its current unaudited accounts at 20 June, it is trading ahead of market expectations for its full financial year ending...

Thu, 21/06/2018 - 07:38

Physiomics wins UK government grant for cancer treatment study

Physiomics, a provider of technology-based solutions to predict the effects of cancer treatment regimens, said it had been awarded a grant by the UK government....

Wed, 14/03/2018 - 09:29

Physiomics signs up 'major' pharmaceutical client

Physiomics said it had been awarded a contract by a 'global top-10' pharmaceutical client, without being more specific.

The project had a value of £70k...

Fri, 09/02/2018 - 07:24